TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07759128: A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 576 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,071,600

Rescue Site Savings

+$4,667,256

Unlock Full NCT07759128 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07759128 Rescue Dossier →